MedPath

CHG Dressings in Children With Central Lines

Not Applicable
Terminated
Conditions
Children With Central Venous Access
Interventions
Other: Tegaderm CHG clear dressing
Other: Standard clear Tegaderm dressing
Registration Number
NCT01955226
Lead Sponsor
Yale University
Brief Summary

The purpose of this study is to determine whether Tegaderm CHG clear dressing reduces the number of unscheduled central catheter dressing changes compared to standard clear Tegaderm IV dressing in pediatric patients between the ages of 2 months to 18 years with central venous access. Secondarily, we will monitor contact skin irritation and central line associated blood stream infections.

Detailed Description

In this prospective, randomized, cohort study, we plan on enrolling all patients 2 months to 18 years of age admitted with a central venous catheter expected to be in place for \> 48 hours. Patients will be randomized to either receive 1) Tegaderm CHG clear dressing or 2) standard clear Tegaderm IV dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital. Study completion will occur at the time of central line removal or discharge from the hospital, whichever comes first.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • All patients 2 months to 18 years of age admitted with a central venous catheter expected to be in place for > 48 hours.
Read More
Exclusion Criteria
  • Patients with known allergies to chlorhexidine or Tegaderm and those previously enrolled in this study will be excluded.
  • Patients with portacatheters
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tegaderm CHG clear dressingTegaderm CHG clear dressingPatients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
Standard clear Tegaderm dressingStandard clear Tegaderm dressingPatients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
Primary Outcome Measures
NameTimeMethod
Reduction in unscheduled central catheter dressing changesStudy completion (Study completion will occur at the time of central line removal or discharge from the hospital, whichever comes first). On average 2 weeks.

The policy at our institution is to change central catheter dressings every 7 days unless they are soiled or detached. We will document dressing changes for the duration of line use and document the reason for the dressing change.

Secondary Outcome Measures
NameTimeMethod
Blood Stream InfectionDischarge (at 2 weeks or more)

Blood stream infections will be tallied and reported per 1,000 central line days. Infection is attributed to the line if a culture becomes positive when the line is in up to 48 hours after removal.

Skin irritationStudy completion (Study completion will occur at the time of central line removal or discharge from the hospital, whichever comes first). On average 2 weeks.

Skin irritation will be assessed using the Scoring of patch tests according to the International Contact Dermatitis Research Group. Scores of 0 are defined as no irritation, 1/2-1+ as minor irritation whereas scores greater than or equal to 2+ will be classified as severe and will require dressing removal.

The clinical team will photograph each central line insertion site with every dressing change and save the most severe skin irritation photo for analysis. These pictures will be sequentially numbered and a master list will link them to each patient.

Trial Locations

Locations (1)

Yale University

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath